Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene's CNM-Au8 ^® treatment was demonstrated to improve survival in ALS patients by up to 14.8 months.

The findings come from a post hoc analysis of the HEALEY ALS Platform Trial, comparing CNM-Au8 to a concurrently enrolled control.

Strong survival benefit was observed in patients meeting the planned criteria for Clene's upcoming Phase 3 RESTORE-ALS trial.

The company is preparing to submit a New Drug Application ("NDA") to the FDA later this year for potential accelerated approval, and further regulatory discussions and a confirmatory Phase 3 trial are planned for mid-2025.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"), has released new data showing that its lead drug candidate, CNM-Au8, significantly extends survival in patients with ALS. The findings were derived from a cross-regimen post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants ( https://ibn.fm/EgWeb ).

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Wednesday's trading session at $4.31, off by 3.3632%, on 47,853 volume. The average volume for the last 3 months is 41,931 and the stock's 52-week low/high is $3.8181/$9.2.

Recent News

• Clene Inc. (NASDAQ: CLNN) - Clene Inc.'s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data
• Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference
• BioMedNewsBreaks - Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients 

Adageis

The QualityStocks Daily Newsletter would like to spotlight Adageis

Adageis was featured in a recent article that discussed the company's positioning as healthcare shifts toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. "While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures that can be difficult to navigate," the article reads.

"One of the major challenges in the marketplace is the sheer complexity… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient's insurance," Adageis CEO Shane Speirs was quoted as saying. "We offer a solution that meets everyone's needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with. Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars."

To view the full article, visit https://ibn.fm/yypjt

Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative solutions. By integrating artificial intelligence (AI) and machine learning, Adageis addresses inefficiencies in healthcare delivery, enabling providers to enhance patient outcomes and streamline operations. The company focuses on leveraging advanced technology to meet the growing demand for value-based care and quality incentives in the healthcare sector.

With a commitment to innovation and practical solutions, Adageis empowers clinics, healthcare centers, and care networks to implement its ProActive Care Platform without the need for expensive platform changes or extensive staff training. This approach reduces barriers to adoption and helps healthcare organizations maximize their potential in an increasingly complex industry landscape.

Recent collaborations, including its partnership with HealthyU Clinics and integration with AthenaHealth as a marketplace partner, underscore Adageis’s industry relevance and adaptability.

Adageis is headquartered in Mesa, Arizona.

Services

Adageis offers the ProActive Care Platform, an AI-driven solution designed to integrate seamlessly with existing Electronic Medical Records (EMR) systems.

This platform enables healthcare providers to deliver patient-centric care while maximizing reimbursements from quality metrics and value-based contracts. Key features include:

• Predictive Analytics: Utilizes AI to analyze patient data, identifying high-risk individuals and care gaps to improve health outcomes and reduce costs.
• Efficiency and Cost Reduction: Continuously monitors patient health, allowing providers to offer proactive care even outside traditional office visits, thereby enhancing efficiency and lowering expenses.
• Flexible Integration: Compatible with various EMR systems, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, facilitating easy adoption without the need for extensive staff training or platform changes.

Market Opportunity

The global AI in healthcare market is experiencing rapid growth, driven by the increasing demand for enhanced efficiency, accuracy, and better patient outcomes. In 2023, the market was valued at approximately $19.27 billion by Grand View Research, and it is projected to grow at a compound annual growth rate of 38.5% from 2024 to 2030. This growth is fueled by the increasing need for solutions that can analyze large datasets, reduce costs, and improve care delivery across the healthcare continuum.

Adageis is well-positioned to capitalize on these trends. Its ProActive Care Platform offers AI-driven predictive analytics and proactive care solutions that align with the industry’s shift toward value-based care. By providing seamless integration with existing EMR systems and focusing on operational efficiency, Adageis enables healthcare providers to meet the demands of a rapidly evolving market.

Leadership Team

Shane Speirs, MD, MBA serves as the company’s CEO. He is a board-certified physician in family and geriatric medicine with extensive experience in healthcare leadership, data modeling, and AI applications in healthcare delivery. He holds an MBA in Healthcare Management from the W.P. Carey School of Business and has a proven track record in managing telehealth and AI-focused healthcare companies.

Bill Jentarra, MBA is the CTO of Adageis, bringing over 25 years of experience in architecting and implementing complex client relationship management (CRM) and business intelligence (BI) solutions across various industries, including healthcare. His expertise encompasses the entire lifecycle of CRM and BI projects, ensuring practical and cost-effective technology applications to solve complex business problems.

Recent News

• Adageis - InvestorNewsBreaks – Adageis Navigates Complexities of Value-Based Care with Tailored Solution
• InvestorNewsBreaks – Adageis’ AI-Driven Approach: A Game-Changer in Efficient, Patient-Centered Healthcare
• Adageis to Launch Series A Funding Round, Seeking $10M in Growth Capital

Thumzup Media Corp. (NASDAQ: TZUP)

The QualityStocks Daily Newsletter would like to spotlight Thumzup Media Corp.(NASDAQ: TZUP).

Thumzup (NASDAQ: TZUP) is leveraging its proprietary social media marketing platform, AdTech, which drives influencers to catapult the effectiveness of small-business advertising. Having achieved a growth rate of over 200% CAGR, Thumzup now serves more than 700 clients, with projections to exceed 1,000 by the next financial quarter. As social media marketing continues to grow, Thumzup's innovative platform allows brands to easily customize campaigns and incentivizes influencer engagement with direct cash rewards, making it a disruptive force in the industry. CEO Robert Steele attributed the company's growth as a testament to the effectiveness of its model, stating, "Our rapid growth to more than 700 advertisers, up from around 200 this time last year, is confirmation of the effectiveness of our disruptive advertising model."

To view the full article, visit https://ibn.fm/3nwJv

Thumzup Media Corp. (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage, and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment, and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

Thumzup Media Corp. (NASDAQ: TZUP), closed Wednesday's trading session at $3.63, even for the day, on 76,900 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.02/$7.89.

Recent News

• Thumzup Media Corp. (NASDAQ: TZUP) - TechMediaBreaks - Thumzup Media Corp. (NASDAQ: TZUP) Fuels Explosive Growth with Disruptive AdTech Platform
• Thumzup Media (NASDAQ: TZUP) Already Tops 700 Businesses Using New Social Media Marketing Solution
• TechMediaBreaks - Thumzup Media Corp. (NASDAQ: TZUP) Announces $1 Million Share Repurchase Program 

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

California recently extended a ban on intoxicating hemp products with THC that was set to expire before the end of March. This comes just months after the ban went into effect following legislators' failure to approve a measure that would've regulated these products. Gov. Gavin Newsom first introduced the ban in September 2024, with the Office of Administrative Law approving the emergency rules that same month. Under the ban, the sale of consumable hemp products with any amount of THC was forbidden. General Counsel of the U.S. Hemp Roundtable, Jonathan Miller, claimed that the governor imposed a complete ban on these products instead of addressing concerns raised and implementing a law to regulate hemp products that was approved a few years prior. Miller added that the state needed to ensure every product in the marketplace was tested and AB 45 was enforced. However, the regulated marijuana industry welcomed the move to tighten hemp regulations, with many arguing that every intoxicating cannabinoid, whether from marijuana or hemp, needed to undergo the same lab tests for contaminants like mold, heavy metals and pesticides. Additionally, some noted that hemp products need to be managed under marijuana's regulatory structure and be subjected to the same packaging and marketing standards. A notice to extend the ban filed by California's public health department allows the rules to continue for another ninety days. Hemp industry actors like Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) with a national outlook will be tracking how California decides on matters of hemp regulation since any laws passed in this state could provide a blueprint for other states around the country.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Wednesday's trading session at $0.01, even for the day, on 10,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0071/$0.06.

Recent News

• Software Effective Solutions Corp. (OTC: SFWJ) - California Extends Prohibition of Hemp Products with THC
• Poll Finds More Consumers Want to Use Hemp Delivery Services
• Hemp Seeds Are Attracting Attention as an Alternative Source of Protein

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

The rise of Web3 is revolutionizing how we interact with the internet, shifting from centralized platforms to decentralized systems that prioritize user ownership and transparency. As this new digital landscape evolves, companies are looking for skilled professionals to build, manage, and enhance decentralized applications (DApps), smart contracts, and blockchain ecosystems. Web3 is not just a buzzword—it's the future of the internet. Whether you're a developer, designer, marketer, or strategist, there's a place for you in this evolving industry. By learning the right skills and staying updated on blockchain trends, you can position yourself for success in the Web3 job market. If you're looking to enter Web3, now is the perfect time to start learning and exploring opportunities in this rapidly growing space. For companies like NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), the innovations that skilled Web3 workers introduce provide avenues for enhanced service delivery.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

• E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
• Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
• NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
• Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Wednesday's trading session at $0.951, up 0.1052632%, on 14 volume. The average volume for the last 3 months is 44,315 and the stock's 52-week low/high is $0.71/$2.68.

Recent News

• NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) - Why Volatility Management is Critical on Web3 Platforms
• Web3 Aims to Transform the Healthcare Industry
• Upcoming Amsterdam Blockchain Week to Showcase Web3 Collaboration and Innovation

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

The QualityStocks Daily Newsletter would like to spotlight Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).

Tonix Pharmaceuticals (NASDAQ: TNXP) announced its fourth-quarter and full-year 2024 financial results, alongside key operational updates. The company highlighted preparations for the potential commercial launch of TNX-102 SL for fibromyalgia in Q4 2025, pending FDA approval with a PDUFA date set for Aug. 15, 2025. Tonix remains debt-free, with cash resources projected to support operations into early 2026. The company also reported progress across its pipeline, including TNX-1500 for kidney transplant rejection, TNX-801 for mpox and smallpox, and TNX-1300 for cocaine intoxication. For Q4 2024, net product revenue reached $2.6 million, while the company reported a net loss of $22.1 million. Full-year 2024 net loss was $130 million, with R&D expenses reduced to $40 million from $86.7 million in 2023 due to pipeline prioritization.

To view the full press release, visit https://ibn.fm/JhUrr

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a fully-integrated biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics aimed at treating and preventing human diseases and alleviating suffering. The company’s development portfolio is primarily focused on central nervous system (CNS) disorders, with its lead product candidate, TNX-102 SL, showing significant promise for the management of fibromyalgia. With two successful Phase 3 studies completed, Tonix is preparing to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, which has also been granted Fast Track designation. In addition to fibromyalgia, TNX-102 SL is being developed to treat acute stress reactions, further broadening its therapeutic potential.

Tonix’s CNS portfolio also includes TNX-1300, a biologic designed to treat cocaine intoxication, which has been granted Breakthrough Therapy designation by the FDA. This designation underscores the urgency and significance of developing an effective treatment for cocaine intoxication, a critical need in the healthcare system. Beyond CNS disorders, Tonix is expanding its immunology portfolio with the development of TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154). TNX-1500 is being developed for the prevention of allograft rejection and the treatment of autoimmune diseases, highlighting Tonix’s commitment to addressing complex and challenging medical conditions.

In addition to its robust pipeline, Tonix has an established commercial presence through its subsidiary, Tonix Medicines, which markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine in adults. The company’s diverse portfolio, spanning CNS disorders, immunology, rare diseases, and infectious diseases, positions Tonix as a leader in biopharmaceutical innovation, with a strong focus on developing therapies that address unmet medical needs and improve patient outcomes.

TNX-102 SL

TNX-102 SL is a groundbreaking, non-opioid, non-addictive investigational drug developed by Tonix Pharmaceuticals for the management of fibromyalgia where patients suffer chronic musculoskeletal pain, sleep deprivation, fatigue and mood changes. This patented sublingual formulation of cyclobenzaprine hydrochloride has demonstrated remarkable efficacy in clinical trials, including the recent RESILIENT Phase 3 trial, where it achieved highly statistically significant results in reducing daily pain compared to placebo (p=0.00005). The drug also showed significant improvements in sleep quality, fatigue reduction, and overall fibromyalgia symptoms and function across all key secondary endpoints. With similar success in the earlier RELIEF Phase 3 trial, TNX-102 SL is positioned as a promising new treatment option for fibromyalgia, particularly given its favorable safety profile, where the most common side effect was mild and self-limiting tongue or mouth numbness.

Recently granted Fast Track Designation by the FDA, TNX-102 SL is on course for a New Drug Application (NDA) submission in the second half of 2024. This designation highlights the urgent need for new fibromyalgia treatments and underscores the drug’s potential to effectively address this challenging condition. With its strong clinical results and focus on improving multiple aspects of fibromyalgia, TNX-102 SL offers hope for patients seeking better management of their symptoms and represents a significant advancement in the treatment landscape for this debilitating disorder.

Market Opportunity

From an investment perspective, Tonix Pharmaceuticals is strategically positioned to capitalize on the growing demand for effective treatments in the central nervous system (CNS) disorder market, particularly within the fibromyalgia segment, which is estimated to affect up to 10 million people in the U.S. alone. With the potential approval of TNX-102 SL, Tonix could tap into a significant and underserved market, offering a non-opioid alternative for a condition that currently has limited treatment options. The recent positive results from the Phase 3 trials and the FDA’s Fast Track designation increase the likelihood of TNX-102 SL gaining market approval, which could significantly boost Tonix’s market share and revenue potential.

In addition to its lead candidate, Tonix’s diversified pipeline, which includes treatments for conditions such as cocaine intoxication and autoimmune diseases, broadens market opportunities and reduces single product dependency. The company’s established commercial presence with its migraine treatments, combined with the advancement of its CNS and immunology portfolios, positions Tonix to become a key player in the biopharmaceutical industry. As the company moves closer to potential product launches and reached new clinical milestones, it stands to attract substantial investor interest, offering significant upside potential as it addresses critical unmet needs across multiple therapeutic areas.

Leadership Team

Dr. Seth Lederman is the Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, bringing decades of experience in the biotechnology and pharmaceutical industries. A trained physician and scientist, Dr. Lederman has been instrumental in leading Tonix’s strategic direction and advancing its pipeline of innovative therapeutics. He has a strong background in immunology and infectious diseases, with numerous contributions to medical research and drug development. Dr. Lederman earned his MD from Columbia University, where he also served as an Associate Professor.

Dr. Gregory Sullivan is the Chief Medical Officer of Tonix Pharmaceuticals, where he oversees the clinical development and regulatory strategy for the company’s therapeutic programs. With extensive experience in psychiatry and CNS disorders, Dr. Sullivan plays a key role in guiding Tonix’s clinical trials and ensuring the scientific rigor of its development efforts. Before joining Tonix, Dr. Sullivan had a distinguished career in academic medicine and clinical research. He holds an MD from the University of California, San Francisco, and has published widely on topics related to psychiatry and neurological disorders.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), closed Wednesday's trading session at $16.47, off by 19.7759%, on 45,347 volume. The average volume for the last 3 months is 1,518,902 and the stock's 52-week low/high is $6.76/$1184.

Recent News

• Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) - InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4, Full-Year 2024 Financial Results, Highlights Key Developments
• InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 BIO-Europe Spring Convention
• BioMedNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances TNX-1500 to Address Organ Transplant Rejection

Standard Lithium Ltd. (NYSE American: SLI)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (NYSE American: SLI).

Standard Lithium (NYSE American: SLI) announced the appointment of Karen G. Narwold as an independent director to its board. Narwold brings over 30 years of leadership experience in manufacturing and chemicals, most recently serving as Chief Administrative Officer, General Counsel, and Corporate Secretary at Albemarle Corporation. Her expertise in legal, governance, regulatory, and operational matters is expected to support Standard Lithium's development of lithium projects in the Smackover formation. Narwold also serves on the board of Ingevity Corporation and chairs its Sustainability & Safety Committee.

To view the full press release, visit https://ibn.fm/PieKK

Standard Lithium Ltd. (NYSE American: SLI) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (NYSE American: SLI), closed Wednesday's trading session at $1.3, off by 5.1095%, on 1,873 volume. The average volume for the last 3 months is 1,151,318 and the stock's 52-week low/high is $1.05/$2.64.

Recent News

• Standard Lithium Ltd. (NYSE American: SLI) - InvestorNewsBreaks - Standard Lithium Ltd. (NYSE American: SLI) Appoints Karen G. Narwold to Board of Directors
• GreenEnergyBreaks - Standard Lithium Ltd. (NYSE American: SLI) Achieves Key Milestone in Smackover Lithium JV DLE Process 
• GreenEnergyBreaks - Standard Lithium Ltd. (NYSE American: SLI) to Participate in 37th Annual Roth Conference 

Datavault AI Inc. (NASDAQ: DVLT)

The QualityStocks Daily Newsletter would like to spotlight Datavault AI Inc. (NASDAQ: DVLT).

Datavault AI (NASDAQ: DVLT) announced that Realtek will showcase a new set-top box software development kit (SDK) featuring WiSA E technology at the Convergence India Expo from March 19-21, 2025. The SDK delivers 5.1 spatial audio without added transmitter hardware costs, offering manufacturers a cost-effective way to enhance home entertainment experiences. Datavault AI's collaboration with Realtek aligns with India's push for AI and blockchain integration, positioning its patented Data Vault® and ADIO® solutions for enterprise adoption in government, finance, and smart infrastructure. With India's AI market projected to reach $17 billion by 2027, Datavault AI sees this partnership as a significant opportunity for expansion and data monetization.

To view the full press release, visit https://ibn.fm/PDz6d

Datavault AI Inc. (NASDAQ: DVLT) is a pioneering leader in immersive, wireless sound technology, providing cutting-edge audio solutions for intelligent devices and next-generation home entertainment systems. The company collaborates with top consumer electronics (CE) brands and manufacturers, including industry giants like Harman International (a division of Samsung), LG, Hisense, TCL, Bang & Olufsen, and Platin Audio. WiSA Technologies delivers exceptional wireless sound experiences for high-definition content, including movies, music, sports, gaming, and esports, thereby enhancing the overall consumer experience in home entertainment.

As a founding member of WiSA™ (the Wireless Speaker and Audio Association), WiSA Technologies plays a critical role in defining wireless audio interoperability standards, ensuring seamless integration across devices and platforms. The company actively works with leading consumer electronics companies, technology providers, retailers, and ecosystem partners to promote and market spatial audio technologies, underscoring its commitment to advancing the future of audio and making high-quality, immersive sound accessible to a broader audience.

Headquartered in Beaverton, Oregon, WiSA Technologies extends its global reach with sales teams strategically located in Taiwan, China, Japan, Korea, and California. This international presence allows the company to effectively serve a diverse customer base and maintain strong relationships with key partners worldwide. By continuously innovating and setting new benchmarks in wireless audio, WiSA Technologies is well-positioned to remain at the forefront of the evolving home entertainment landscape.

The WiSA Association

The WiSA® Association, a wholly owned subsidiary of WiSA Technologies, is dedicated to promoting and standardizing spatial audio solutions for home entertainment, ensuring that immersive audio experiences are accessible to everyone. In collaboration with leading consumer electronics companies, technology providers, retailers, and ecosystem partners, the association works to advance wireless audio technology across various devices, making high-quality sound an integral part of modern home entertainment systems. As a key player in the industry, WiSA LLC, also known as the Wireless Speaker and Audio Association, is instrumental in fostering the adoption and integration of cutting-edge audio technologies.

Recently, the WiSA Association significantly expanded its influence by executing licensing agreements with leading HDTV brands, covering 43% of the HDTV market that uses the Android operating system, the most widely used OS in the market. By focusing on Android-based HDTVs and collaborating with speaker manufacturers, WiSA is actively building an ecosystem of WiSA E-enabled speaker systems, mirroring the success of its earlier WiSA HT technology. This strategic initiative, combined with WiSA E’s compatibility with multiple HDTV SoC providers and support for spatial audio formats like Dolby Atmos FlexConnect, positions the association at the forefront of transforming home audio experiences, driving widespread adoption across the home entertainment landscape.

Market Opportunity

From an investment perspective, WiSA Technologies Inc. is strategically positioned to capitalize on the growing demand for wireless and immersive audio experiences as consumer preferences shift toward high-definition home entertainment systems. As streaming services, gaming, and smart home technologies continue to expand, the need for seamless, high-quality audio solutions is becoming increasingly critical. WiSA Technologies, with its innovative wireless sound technology and strong partnerships with leading consumer electronics brands, is well-placed to capture a significant share of this expanding market, particularly as more consumers seek to enhance their home entertainment experiences.

Moreover, the company’s focus on setting industry standards through the WiSA Association further solidifies its role as a key player in the evolving audio landscape. By driving the adoption of wireless audio interoperability standards, WiSA Technologies not only ensures broad compatibility across devices but also positions itself as a leader in the market, capable of influencing future trends and technologies. This proactive approach, combined with its established global presence and collaborations with top-tier brands, provides WiSA Technologies with a strong foundation for sustained growth, making it an attractive opportunity for investors looking to gain exposure to the burgeoning home entertainment and smart audio sectors.

Leadership Team

Brett Moyer is the Chief Executive Officer, President, and Chairman of WiSA Technologies, Inc., and a founding member of the company. He has served in these leadership roles since August 2010. Prior to this, Mr. Moyer was the president and CEO of Focus Enhancements, Inc., where he oversaw the development and marketing of proprietary video technology. He has a rich background in consumer electronics, having held key positions at Zenith Electronics Inc., including Vice President and General Manager of its Commercial Products Division. Mr. Moyer also serves on the board of directors of Alliant International University and has previously served on the boards of HotChalk, Inc., and NeoMagic Corporation. He holds a Bachelor of Arts in Economics from Beloit College and an MBA in Finance and Accounting from Thunderbird School of Global Management.

Gary Williams is the Chief Accounting Officer and Vice President of Finance at WiSA Technologies, Inc., roles he has held since September 2019 and the company’s founding in August 2010, respectively. He previously served as the company’s Chief Financial Officer and Secretary until 2019. Mr. Williams has extensive experience in finance, having served as CFO of Quantum3D, Inc., and in similar roles at Focus Enhancements Inc. and Videonics Inc. He began his career in public accounting with Coopers & Lybrand LLP. Mr. Williams is a certified public accountant (inactive) and holds a bachelor’s degree in business administration with an emphasis in accounting from San Diego State University.

Datavault AI Inc. (NASDAQ: DVLT), closed Wednesday's trading session at $0.9342, off by 2.6976%, on 2,674 volume. The average volume for the last 3 months is 2,286,758 and the stock's 52-week low/high is $0.693/$10.95.

Recent News

• Datavault AI Inc. (NASDAQ: DVLT) - AINewsBreaks - Datavault AI Inc. (NASDAQ: DVLT) Partners with Realtek to Showcase WiSA E Tech at Convergence India Expo 
• InvestorNewsBreaks - Datavault AI Inc. (NASDAQ: DVLT) Announces WiSA SoundSend Certification for Optoma HCPro-4400 Projector
• InvestorNewsBreaks - WiSA Technologies Inc. (NASDAQ: WISA) Rebrands as Datavault AI Inc. (NASDAQ: DVLT)

Oragenics Inc. (NYSE American: OGEN)

The QualityStocks Daily Newsletter would like to spotlight Oragenics Inc. (NYSE American: OGEN).

Oragenics (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025. The company's audited financial statements received an unqualified audit opinion, though an explanatory paragraph raised concerns about its ability to continue as a going concern. Oragenics remains focused on advancing its pipeline of treatments for concussion and brain-related health conditions while pursuing strategic opportunities to ensure long-term growth. Further details are available in Footnote 1 of the financial statements.

To view the full press release, visit https://ibn.fm/BrTCE

Oragenics Inc. (NYSE American: OGEN) is a development-stage biotechnology company pioneering innovative solutions in pharmaceutical medications, with a focus on nasal delivery systems. The company addresses critical unmet medical needs in neurology and infectious diseases, with research centered on developing drug candidates for mild traumatic brain injuries, such as concussions, and rare neurodegenerative disorders like Niemann-Pick Disease Type C. These areas represent significant challenges within the medical community due to limited treatment options making Oragenics’ mission especially impactful.

A key differentiator for Oragenics is its proprietary powder formulation technology, which enhances the stability and efficacy of pharmaceutical compounds. Combined with an advanced intranasal delivery device, this technology allows for administration intracellularly to the central nervous system, potentially offering more effective and faster-acting treatments.

The company’s focus on intranasal delivery also enables more patient-friendly and non-invasive treatment options, a growing area of interest in modern therapeutics. Beyond neurology, Oragenics is also targeting infectious diseases, leveraging its unique platform to position itself as a leader in cutting-edge biopharmaceutical solutions.

ONP-002

Oragenics’ lead candidate, ONP-002, is an innovative intranasal treatment for concussions that offers significant logistical advantages, including stability across a wide temperature range, eliminating the need for cold storage. This makes it ideal for varied environments such as sports fields or military operations. The drug is administered via a breath-propelled delivery system that diffuses intracellularly and activates gene response elements leading to the production of proteins that reduce inflammation, oxidative stress, and swelling to quickly, safely, and effectively counteract the harmful effects of a concussion.

Oragenics recently completed the synthesis of the ONP-002 batch for a planned Phase II clinical trial, with testing demonstrating over 99% purity after three months of stability. With an estimated 69 million concussions globally each year, ONP-002 could represent a major advancement in rapid response acute concussion treatment, offering new hope for reducing long-term disabilities associated with these injuries.

Market Opportunity

Oragenics offers a strong investment opportunity due to its focus on addressing large unmet needs in the neurology market, particularly with ONP-002, which targets the broad growing demand for concussion treatments.

The company’s proprietary intranasal delivery technology also opens up broader applications beyond concussion treatment, presenting additional revenue opportunities. As Oragenics advances through clinical trials, positive results could boost its valuation and attract attention from pharmaceutical heavyweights, positioning it as a promising player in the biotech industry.

Leadership Team

J. Michael Redmond, President & Interim Principal Executive Officer, has over 35 years of commercial experience in the biotech and medical device industries. He has held pivotal roles at companies such as Abbott Laboratories and KMC Systems Inc., where he helped grow the company to over $50M in revenue before its acquisition by Elbit Systems. As VP of Sales and Marketing at Bioject Inc., he was instrumental in raising capital and expanding the company’s market cap from under $10M to over $400M. Most recently, Mr. Redmond served as CEO of Odyssey Health Inc.

Janet Huffman, Chief Financial Officer, brings extensive financial expertise from her role as CFO of TRxADE HEALTH Inc., a Nasdaq-listed health services IT company. She was a founding member and CFO of Banyan Pediatric Care Centers, later leading its merger with Assisted 4 Living Inc. (now Arboreta Healthcare Inc.), where she continued as CFO until 2022. Ms. Huffman has also held senior finance roles at Signature HomeNow, Infinity Homecare, and Family Home Health Services. She holds both a bachelor’s and a master’s degree in accounting from the University of South Florida.

Oragenics Inc. (NYSE American: OGEN), closed Wednesday's trading session at $0.2546, off by 2.0769%, on 4,602 volume. The average volume for the last 3 months is 528,353 and the stock's 52-week low/high is $0.243/$3.43.

Recent News

• Oragenics Inc. (NYSE American: OGEN) - InvestorNewsBreaks - Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status
• BioMedNewsBreaks - Oragenics Inc. Advances Concussion Treatment with Phase II Trial Preparation 
• BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Highlights Concussion Treatment Advances at Emergencies in Medicine Conference

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF)

The QualityStocks Daily Newsletter would like to spotlight G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF).

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) announced that its common shares have been included in several major stock indices, including the NYSE Arca Gold Miners Index (GDX), MVIS Global Junior Gold Miners Index (GDXJ), S&P/TSX Composite Index (GSPTSE), and iShares MSCI Canada ETF (EWC). President and CEO Louis-Pierre Gignac stated that the inclusions reflect the company's commitment to executing its self-perform approach and advancing its gold projects, including the Tocantinzinho Gold Mine. These index additions are expected to enhance trading liquidity and attract institutional investment. The rebalancing for GDX, GDXJ, and GSPTSE is set for March 21, 2025, while EWC was rebalanced on Feb. 28, 2025.

To view the full press release, visit https://ibn.fm/3hncq

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) is a mineral exploration company engaged in the acquisition, exploration and development of precious metal projects to capitalize on the value uplift from successful mine development. The company’s mission is to acquire, build and operate sustainable precious metal mining operations using its proven “self-perform” approach, while focusing on the health and safety of its employees and host communities first.

In 2020, G Mining Ventures was created to acquire direct ownership of projects. With strong access to capital via a supportive shareholder base, coupled with proven development expertise, the company is well positioned to become the next mid-tier precious metal producer.

G Mining Ventures is currently anchored by its flagship asset, the 100%-owned Tocantinzinho Project (TZ), in mining friendly Para State, Brazil. TZ is an open-pit gold deposit containing around 2 million ounces of reserves at 1.3 grams per ton. The deposit is open at depth, and an underexplored 688-square-kilometer land package presents additional exploration potential.

G Mining strives to include all stakeholders in its journey toward creating exceptional value, including major shareholders, government organizations, local communities and employees, among others. In order to facilitate that inclusion, regular communications are coordinated to convey material developments and solicit feedback from interested parties.

The company is headquartered in Brossard, Québec.

Project Portfolio

Tocantinzinho

Tocantinzinho (TZ) was acquired in 2021 and construction was launched in September 2022, following completion of a Definitive Feasibility Study (DFS) which confirmed TZ’s potential to be a cornerstone asset for G Mining. The DFS contemplates a 10.5-year mine life with an average annual gold production of 175,000 ounces and an initial capital cost of $458 million. The DFS displayed robust economics at a $2,000 per ounce gold price assumption, including an after-tax NPV 5% of $1 billion and an after-tax IRR of 34%.

The first pour at TZ yielded approximately 440 ounces of gold, and the project remains on time and budget for commercial production in the second half of 2024. Once in commercial production, TZ is expected to become Brazil’s third-largest primary gold mine.

Since the start of hot commissioning in June 2024 approximately 77,000 tons of ore have been processed through the TZ process plant, with all circuits operating as expected.

Oko West

In July 2024, through its business combination with Reunion Gold Corp., G Mining acquired Reunion’s flagship Oko West Project located in Guyana within the Guiana Shield region, one of the most attractive mining jurisdictions in South America. Oko West has emerged as a globally significant gold discovery over the last few years, with excellent potential to become a top tier deposit that could support a large, long-life mine complex to accelerate G Mining’s vision of building a leading intermediate gold producer.

The company plans to move Oko West quickly through technical studies to a construction decision, leveraging the considerable amount of exploration, development and permitting work that has already been completed, supported by the expected free cash flow stemming from TZ.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council. In July 2024, the market price of gold was approximately $2,450 per ounce.

Management Team

Louis-Pierre Gignac, P. Eng., CFA, is Co-Founder, President and CEO of G Mining Ventures. He has more than 20 years of experience in the mining industry and has coordinated many mandates with numerous major mining companies, ranging from early exploration evaluations to operations optimization involving all fields of mining and geology. He is a member of the Ordre des Ingénieurs du Québec and the Canadian Institute of Mining. He holds a Bachelor of Mining Engineering from McGill University and a Master degree of Applied Science in Industrial Engineering from the École Polytechnique de Montréal.

Julie Lafleur, CPA, CA, is Vice President, Finance and CFO of G Mining Ventures. She has been a Chartered Professional Accountant in Québec since 1998 and has 20 years of experience in the mining industry. After four years with accounting firm Raymond Chabot Grant Thornton, she started with Cambior Inc. as accounting analyst and took on various positions of increasing responsibility with Niobec Inc., Iamgold Essakane S.A., Newmont Suriname LLC and Aurelian Ecuador S.A., a subsidiary of Lundin Gold Inc. She holds a bachelor’s degree in business administration from l’École des Hautes Études Commerciales of Montreal.

Dušan Petković, CFA, is Co-Founder and Senior Vice President, Corporate Strategy of G Mining Ventures. He is a financial market professional with over 15 years of experience in resource-based capital markets, including private equity, credit and investment banking. Before joining G Mining, he was a Principal of Private Debt at Sprott Resource Lending Corp. Before that, he spent time in mining investment banking, advising on IPOs, equity issuance and M&A. He earned a Bachelor of Commerce degree from Western University.

G Mining Ventures Corp. (OTCQX: GMINF), closed Wednesday's trading session at $13.23, up 2.582%, on 173,625 volume. The average volume for the last 3 months is 840,890 and the stock's 52-week low/high is $2.85/$13.562.

Recent News

• G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) - InvestorNewsBreaks - G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) Added to Multiple Major Stock Indices
• InvestorNewsBreaks - G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) Begins Site Preparation at Oko West Gold Project
• MiningNewsBreaks - G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) Updates 2024 Mineral Reserves, Resources for Gurupi Project

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Brera Holdings PLC (NASDAQ: BREA), closed Wednesday's trading session at $0.6878, up 9.1746%, on 10,713 volume. The average volume for the last 3 months is 3,498,043 and the stock's 52-week low/high is $0.4999/$1.95.

Recent News

• Brera Holdings PLC (NASDAQ: BREA) - Brera Holdings PLC (NASDAQ: BREA) Bolsters Advisory Board with the Addition of Famed Global Economist Dr. Arthur B. Laffer
• InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Releases Report on Multi-Team Ownership in Women's Soccer 
• InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Hosts Inaugural Investor Weekend at Juve Stabia

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Wednesday's trading session at $0.0349, even for the day, on 7,500 volume. The average volume for the last 3 months is 130,450 and the stock's 52-week low/high is $0.03095/$0.107.

Recent News

• Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) - Congo Freezes Cobalt Exports to Stem Plummeting Prices
• Major Pension Fund Pulls $35 Billion from State Street Over ESG Concerns
• MiningNewsBreaks - Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Announces Initial Mineral Resource Estimate for Storm Copper Project